XML 34 R20.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Investments in Non-Marketable Equity Securities | 12 Months Ended
--- | ---
Dec. 31, 2016
Investments, All Other Investments [Abstract] |
Financial Instruments Disclosure [Text Block] |
| Note 10. | Investments in Non-Marketable Equity Securities
Following is a summary of such investments which are accounted for using the cost method as of December 31, 2015 and 2016:
|  | December 31, |
|  | 2015 |  | 2016 |
|  | (in thousands) |
Chi Lin Optoelectronics Co., Ltd. |  | $ | 625 |  |  | 488 |
Chi Lin Technology Co., Ltd. |  |  | 432 |  |  | 432 |
Jetronics International Corp. |  |  | 432 |  |  | - |
C Company |  |  | 8,962 |  |  | 8,962 |
TIEF Fund, L. P. |  |  | - |  |  | 1,600 |
eTurboTouch Technology Inc. |  |  | 477 |  |  | 477 |
Oculon Optoelectronics Inc. |  |  | - |  |  | - |
Shinyoptics Corp. |  |  | 283 |  |  | 283 |
|  | $ | 11,211 |  |  | 12,242 |
Chi Lin Optoelectronics Co., Ltd. reduced its capital and returned $137 thousand to the Company in December 2016. Jetronics International Corp. reduced its capital and returned $1,168 thousand and $431 thousand to the Company in October 2014 and June 2016, respectively. Jetronics International Corp. was liquidated in September 2016. The Company sold the investments in S Company in March 2014 for proceeds of $4,948 thousand and recognized loss on sale of securities of $241 thousand for the year ended December 31, 2014, which is included in “Gains (losses) on sale of securities, net”. The Company sold the investments in L Company in May 2014 for total proceeds of $16,425 thousand, of which $14,743 thousand received in May 2014 and $1,682 thousand received in May 2015, and recognized gain on sale of securities of $10,743 thousand and $1,682 thousand for the years ended December 31, 2014 and 2015, respectively, which is included in “Gains (losses) on sale of securities, net”. In 2014, management considered the Company’s investment in equity of Oculon Optoelectronics Inc. was impaired as it did not believe that the investment carrying value would be recovered due to the investee’ significant deterioration in the earnings performance. Management believes that Company’s proportionate equity interest in the net book value of the investee is the best estimate of the recoverable amount. As a result, the Company recognized impairment loss of $309 thousand for the year ended December 31, 2014, which is included in “impairment loss on investment”. Oculon Optoelectronics Inc. was liquidated in January 2016. As of December 31, 2015 and 2016, except for the above impaired investments, the fair values of the Company’s investments in non-marketable equity securities were not estimated because management did not identify events or changes in circumstance that may significantly affect the Company’s ability on recovering the carrying values of these investments, and it was not practicable for management to estimate the fair values of these investments due to the lack of quoted market price and the inability to estimate the fair value without incurring excessive costs.

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References No definition available. + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAllOtherInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration